Zitong Zhang

Ms. Zitong Zhang

Huazhong University of Science and Technology
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Energy Reports
Verified
Journal Article
Open access
XDXuzhi Deng
Xuzhi Deng
AYAoshuang Ye
Aoshuang Ye
JZJiashi Zhong
Jiashi Zhong
DXDong Xu
Dong Xu
WYWangwang Yang
Wangwang Yang
XCXiaoyi Chen
Xiaoyi Chen

1 January 2022 in Oncologie
Verified
Journal Article
Open access
PDF file
JSJiajian Shi
Jiajian Shi
YCYuchen Chen
Yuchen Chen
CPChentai Peng
Chentai Peng
LKLinwu Kuang
Linwu Kuang
ZZZitong Zhang
Zitong Zhang
KHKun Huang
Kun Huang
The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been well studied and applied in clinical treatments, which greatly promote the overall survival of NSCLC patients. However, drug resistance has become a major challenge for targeted treatment, and a variety of methods to overcome drug resistance are constantly being developed, including inhibitors against new mutants, combination therapy with other pathway inhibitors, etc. In addition, epigenetics-based therapy is emerging. Epigenetic regulators such as histone deacetylases and non-coding RNA play a crucial role in the development of cancer and drug resistance by affecting multiple signaling pathways. Epigenetics-based therapeutic strategies combined with targeted drugs show great clinical potential. Many agents targeting epigenetic changes are being investigated in preclinical studies, with some already under clinical trials. This article focuses on driver mutations and epigenetic alterations in association with relevant epidemiological data. We introduce the current status of targeted inhibitors and known drug resistance, review advances in major targeted therapies with recent data from preclinical and clinical trials, and discuss the possibility of combination therapy against driver mutations and epigenetic alterations in overcoming drug resistance.

2 November 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
ZZZhiling Zhang
Zhiling Zhang
RLRuiqi Liu
Ruiqi Liu
WWWensu Wei
Wensu Wei
ZZZitong Zhang
Zitong Zhang
PDPei Dong
Pei Dong
Background: Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (mRCC). Methods: We retrospectively reviewed 74 patients treated with non-first-line PD-1 inhibitors plus TA in non-first-line setting. Survival outcomes were calculated from the anti-PD-1 treatment using the Kaplan–Meier method. Univariate and multivariate analyses were performed by Cox proportional hazards models. Results: Thirty-two (43.2%) patients received anti-PD-1/TA therapy alone (anti-PD-1/TA alone group), and 42 (56.8%) received SBRT in addition (anti-PD-1/TA + SBRT group). The median duration of first-line therapy was 8.6 months. Patients in the anti-PD-1/TA + SBRT group had significantly longer overall survival (OS) (38.5 vs 15.4 months; P = 0.022). On multivariate analysis, oligometastasis, ECOG performance status 0–1, anti-PD-1/TA + SBRT, and duration of first-line therapy ≥ 8.6 months were predictors for OS. The addition of SBRT was associated with improved OS in patients with clear-cell type (HR 0.19; 95% CI 0.07–0.55; P = 0.002) and duration of first-line therapy ≥ 8.6 months (HR 0.22; 95% CI 0.06–0.88; P = 0.032). Grade ≥ 3 toxicities occurred in 23 patients (54.8%) in the anti-PD-1/TA + SBRT group, and in 21 patients (65.6%) in the anti-PD-1/TA alone group. Conclusions: Incorporating SBRT into anti-PD-1/TA therapy is safe and tolerable. Further investigation is needed, particularly in patients with clear-cell histology and a longer duration of response to first-line antiangiogenic therapy.

19 October 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
ZSZhaofang Song
Zhaofang Song
Jing ShiJing Shi
Jing Shi
SLShujian Li
Shujian Li
ZCZexu Chen
Zexu Chen
WYWangwang Yang
Wangwang Yang
ZZZitong Zhang
Zitong Zhang
As the electricity consumption and controllability of residential consumers are gradually increasing, demand response (DR) potentials of residential consumers are increasing among the demand side resources. Since the electricity consumption level of individual households is low, residents’ flexible load resources can participate in demand side bidding through the integration of load aggregator (LA). However, there is uncertainty in residential consumers’ participation in DR. The LA has to face the risk that residents may refuse to participate in DR. In addition, demand side competition mechanism requires the LA to formulate reasonable bidding strategies to obtain the maximum profit. Accordingly, this paper focuses on how the LA formulate the optimal bidding strategy considering the uncertainty of residents’ participation in DR. Firstly, the physical models of flexible loads are established to evaluate the ideal DR potential. On this basis, to quantify the uncertainty of the residential consumers, this paper uses a fuzzy system to construct a model to evaluate the residents’ willingness to participate in DR. Then, based on the queuing method, a bidding decision-making model considering the uncertainty is constructed to maximize the LA’s income. Finally, based on a case simulation of a residential community, the results show that compared with the conventional bidding strategy, the optimal bidding model considering the residents’ willingness can reduce the response cost of the LA and increase the LA’s income.

23 March 2022 in IEEE Transactions on Applied Superconductivity
Verified
Journal Article
Closed access
Jing ShiJing Shi
Jing Shi
DLDengquan Lin
Dengquan Lin
MLMeng Liao
Meng Liao
WYWangwang Yang
Wangwang Yang
ZZZitong Zhang
Zitong Zhang
LRLi Ren
Li Ren
The voltage distribution on the magnet of superconducting Magnetic Energy Storage (SMES) system are the result of the combined effect of system power demand, operation control of power condition system (PCS) and magnet parameters, which is a key issue that influence the stability and security of SMES magnet. This paper mainly focuses on the interaction between the different components and the influence factors on voltage distribution on the magnet. Firstly, the hybrid model which integrate the power system dynamics, the detailed device of PCS and the transient model of magnet is built. Then, from the perspective of power requirement of power system, operation mode and control strategy of PCS, the voltage distribution characteristics are comprehensively analyzed. Finally, the optimization design method of operation mode to reduce the unevenness of voltage distribution is proposed.

12 January 2022 in Energies
Verified
Journal Article
Open access
PDF file
ZCZexu Chen
Zexu Chen
Jing ShiJing Shi
Jing Shi
ZSZhaofang Song
Zhaofang Song
WYWangwang Yang
Wangwang Yang
ZZZitong Zhang
Zitong Zhang
In recent years, demand response (DR) has played an increasingly important role in maintaining the safety, stability and economic operation of power grid. Due to the continuous running state and extremely fast speed of response, the aggregated inverter air conditioning (IAC) load is considered as the latest and most ideal object for DR. However, it is easy to cause load rebound when the aggregated IAC load participates in DR. Existing methods for controlling air conditioners to participate in DR cannot meet the following three requirements at the same time: basic DR target, load rebound suppression, and users’ comfort. Therefore, this paper has proposed a genetic algorithm based temperature-queuing control method for aggregated IAC load control, which could suppress load rebound under the premise of ensuring the DR target and take users’ comfort into account. Firstly, the model of the aggregated IAC load is established by the Monte Carlo method. Then the start and end time of DR are selected as the main solution variables. A genetic algorithm is used as the solving tool. The simulation results show that the proposed strategy shows better performance in suppressing load rebound. In the specific application scenario of adjusting the frequency fluctuation of the microgrid, the results of the case show that this strategy can effectively control the frequency fluctuation of the microgrid. The effectiveness of the strategy is verified.